Zoledronic acid 0.04 injectable concentrate solution ^en

mid: /m/0hqrlzg notable type: /medicine/drug_formulation notable for: /medicine/drug_formulation

Zoledronic acid injectable concentrate solution, for intravenous administration, consisting of: 0.04mg/mL zoledronic acid.Indications:Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1)Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not been established for use in hyperparathyroidism or nontumor-related hypercalcemia. (1.3) [ - ]

Types:

Add type

Metaweb System Types

Object

Common

Topic

Medicine

Drug formulation

Freebase

Object profile

Object is not asserted on this topic.

ID /type/object/id

GUID /type/object/guid

#9202a8c04000641f800000001f6bcbce

Type /type/object/type

Topic
Drug formulation

Name /type/object/name

- - Edit
  - Delete
Zoledronic acid 0.04 injectable concentrate solution

Key /type/object/key

- - Edit
  - Delete
/base/medicaldrugs/fda_load/form_6XC1PAD3KF_0_04mg_mL_injectable_concentrate_solution_intravenous

Timestamp /type/object/timestamp

Saturday, January 07, 2012 7:29 AM

Permission /type/object/permission

/boot/all_permission

Creator /type/object/creator

fda_medical_bot

Attribution /type/object/attribution

fda_medical_bot

Search /type/object/search

Machine ID /type/object/mid

/m/0hqrlzg

Also known as /common/topic/alias

Description /common/topic/description

- - Edit
  - Delete
Zoledronic acid injectable concentrate solution, for intravenous administration, consisting of: 0.04mg/mL zoledronic acid.Indications:Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1)Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not been established for use in hyperparathyroidism or nontumor-related hypercalcemia. (1.3)